Ibrutinib may impair serological responses to influenza vaccination

Abby P Douglas, Jason A Trubiano, Ian Barr, Vivian K Leung, Monica A Slavin, and Constantine S Tam

Disclosures: Peter MacCallum Cancer Centre receives grant support from Merck and Gilead. MS receives honoraria from Merck and Gilead. CT receives research funding and honoraria from Janssen.

Contributions: AD interpreted the data and wrote the paper, JT and CT designed the research study, CT, JT and MS contributed to writing the paper, IB and CT performed the research and VL analysed the data.